MA38935A1 - Dérivés de diazacarbazole à titre de ligands tau-pet - Google Patents
Dérivés de diazacarbazole à titre de ligands tau-petInfo
- Publication number
- MA38935A1 MA38935A1 MA38935A MA38935A MA38935A1 MA 38935 A1 MA38935 A1 MA 38935A1 MA 38935 A MA38935 A MA 38935A MA 38935 A MA38935 A MA 38935A MA 38935 A1 MA38935 A1 MA 38935A1
- Authority
- MA
- Morocco
- Prior art keywords
- fluoro
- aggregates
- dipyrido
- pyridin
- pyrrole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Cette invention concerne un composé de formule générale (i) dans laquelle r est un atome d'hydrogène ou de tritium ; f est un fluoro ou 18fluoro ; ou un sel d'addition d'acide pharmaceutiquement acceptable de celui-ci. Les composés de formule i comprennent le 2-(6-fluoro-pyridin-3-yl)-9h-dipyrido[2,3-b; 3',4'-d]pyrrole, le 3h-2-(6-fluoro-pyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole et le [18f]-2-(6-fluoro-pyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole. Ils peuvent être utilisés pour lier et soumettre à imagerie les agrégats tau et les agrégats de feuillets bêta associés comprenant, entre autres, les agrégats bêta-amyloïdes ou les agrégats d'alpha-synucléine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13187764 | 2013-10-08 | ||
| PCT/EP2014/071283 WO2015052105A1 (fr) | 2013-10-08 | 2014-10-06 | Dérivés de diazacarbazole à titre de ligands tau-pet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38935A1 true MA38935A1 (fr) | 2016-04-29 |
| MA38935B1 MA38935B1 (fr) | 2016-12-30 |
Family
ID=49301396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38935A MA38935B1 (fr) | 2013-10-08 | 2016-03-25 | Dérivés de diazacarbazole à titre de ligands tau-pet |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US10004817B2 (fr) |
| EP (1) | EP3055308B1 (fr) |
| JP (1) | JP6194416B2 (fr) |
| KR (1) | KR101770531B1 (fr) |
| CN (1) | CN105358558B (fr) |
| AR (1) | AR097931A1 (fr) |
| AU (1) | AU2014333996B2 (fr) |
| CA (1) | CA2917191C (fr) |
| CL (1) | CL2016000728A1 (fr) |
| CR (1) | CR20150663A (fr) |
| DK (1) | DK3055308T3 (fr) |
| EA (1) | EA028483B1 (fr) |
| ES (1) | ES2657121T3 (fr) |
| HR (1) | HRP20180049T1 (fr) |
| HU (1) | HUE035413T2 (fr) |
| IL (1) | IL243249A0 (fr) |
| LT (1) | LT3055308T (fr) |
| MA (1) | MA38935B1 (fr) |
| MX (1) | MX373153B (fr) |
| MY (1) | MY190196A (fr) |
| NO (1) | NO3055308T3 (fr) |
| PE (1) | PE20160159A1 (fr) |
| PH (1) | PH12016500249A1 (fr) |
| PL (1) | PL3055308T3 (fr) |
| PT (1) | PT3055308T (fr) |
| RS (1) | RS56777B1 (fr) |
| SG (1) | SG11201602786UA (fr) |
| SI (1) | SI3055308T1 (fr) |
| TW (1) | TWI513698B (fr) |
| UA (1) | UA116164C2 (fr) |
| WO (1) | WO2015052105A1 (fr) |
| ZA (1) | ZA201509013B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011512354A (ja) | 2008-02-14 | 2011-04-21 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経機能障害を検知するための新規の造影剤 |
| PT3055308T (pt) | 2013-10-08 | 2018-01-18 | Hoffmann La Roche | Resumo |
| IL280791B2 (en) | 2014-05-13 | 2024-03-01 | Hoffmann La Roche | Deuterated compounds and uses thereof |
| WO2016124508A1 (fr) | 2015-02-02 | 2016-08-11 | Ucb Biopharma Sprl | Dérivés de 9h-pyrrolo-dipyridine |
| EP3118202A1 (fr) | 2015-07-15 | 2017-01-18 | AC Immune S.A. | Dérivés de dihydropyridopyrrole en tant que ligands tau-pet |
| WO2017009454A1 (fr) | 2015-07-15 | 2017-01-19 | Ac Immune S.A. | Nouveaux composés d'imagerie |
| SG11201811311VA (en) | 2016-07-22 | 2019-01-30 | Ac Immune Sa | Compounds for imaging tau protein aggregates |
| US10865207B2 (en) | 2016-07-22 | 2020-12-15 | Ac Immune S.A. | Compounds for imaging Tau protein aggregates |
| WO2018024642A1 (fr) | 2016-08-02 | 2018-02-08 | Ucb Biopharma Sprl | Dérivés de 9h-pyrrolo-dipyridine |
| WO2018024643A1 (fr) | 2016-08-02 | 2018-02-08 | Ucb Biopharma Sprl | Dérivés de 9h-pyrrolo-dipyridine |
| SG11201901983PA (en) * | 2016-09-09 | 2019-04-29 | Hoffmann La Roche | Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole |
| BR112020014594A8 (pt) * | 2018-01-24 | 2022-12-13 | Ac Immune Sa | Composições de diagnóstico para imageamento pet, método para fabricar composição de diagnóstico e seu uso em diagnóstico |
| CN111868062B (zh) * | 2018-01-24 | 2023-07-07 | Ac免疫有限公司 | 制备显像化合物的方法 |
| EP3743426A1 (fr) | 2018-01-24 | 2020-12-02 | AC Immune SA | Composés d'azacarboline pour la détection d'agrégats de tau |
| EP3743423A1 (fr) | 2018-01-24 | 2020-12-02 | AC Immune SA | Composés gamma-carboline pour la détection d'agrégats de tau |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011512354A (ja) * | 2008-02-14 | 2011-04-21 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経機能障害を検知するための新規の造影剤 |
| US8932557B2 (en) * | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
| ES2392489T3 (es) | 2008-06-11 | 2012-12-11 | Genentech, Inc. | Dicarbazoles y procedimientos de uso |
| WO2010011964A2 (fr) | 2008-07-24 | 2010-01-28 | Siemens Medical Solutions Usa, Inc. | Agents d'imagerie utiles pour identifier une pathologie |
| US8691187B2 (en) * | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2010111303A2 (fr) | 2009-03-23 | 2010-09-30 | Siemens Medical Solutions Usa, Inc. | Agents d'imagerie pour détecter des troubles neurologiques |
| US20110183938A1 (en) | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
| US20150368244A1 (en) * | 2011-01-31 | 2015-12-24 | Genentech, Inc. | Diazacarbazoles and methods of use |
| PT3055308T (pt) * | 2013-10-08 | 2018-01-18 | Hoffmann La Roche | Resumo |
-
2014
- 2014-10-06 PT PT147811699T patent/PT3055308T/pt unknown
- 2014-10-06 AU AU2014333996A patent/AU2014333996B2/en active Active
- 2014-10-06 CN CN201480037389.5A patent/CN105358558B/zh active Active
- 2014-10-06 ES ES14781169.9T patent/ES2657121T3/es active Active
- 2014-10-06 UA UAA201604290A patent/UA116164C2/uk unknown
- 2014-10-06 MY MYPI2016000604A patent/MY190196A/en unknown
- 2014-10-06 KR KR1020167008013A patent/KR101770531B1/ko active Active
- 2014-10-06 PE PE2015002706A patent/PE20160159A1/es active IP Right Grant
- 2014-10-06 SG SG11201602786UA patent/SG11201602786UA/en unknown
- 2014-10-06 HR HRP20180049TT patent/HRP20180049T1/hr unknown
- 2014-10-06 AR ARP140103712A patent/AR097931A1/es active IP Right Grant
- 2014-10-06 LT LTEP14781169.9T patent/LT3055308T/lt unknown
- 2014-10-06 MX MX2016002234A patent/MX373153B/es active IP Right Grant
- 2014-10-06 CA CA2917191A patent/CA2917191C/fr active Active
- 2014-10-06 WO PCT/EP2014/071283 patent/WO2015052105A1/fr not_active Ceased
- 2014-10-06 PL PL14781169T patent/PL3055308T3/pl unknown
- 2014-10-06 SI SI201430549T patent/SI3055308T1/en unknown
- 2014-10-06 NO NO14781169A patent/NO3055308T3/no unknown
- 2014-10-06 DK DK14781169.9T patent/DK3055308T3/en active
- 2014-10-06 EA EA201690515A patent/EA028483B1/ru not_active IP Right Cessation
- 2014-10-06 TW TW103134795A patent/TWI513698B/zh active
- 2014-10-06 EP EP14781169.9A patent/EP3055308B1/fr active Active
- 2014-10-06 RS RS20180058A patent/RS56777B1/sr unknown
- 2014-10-06 HU HUE14781169A patent/HUE035413T2/en unknown
- 2014-10-06 JP JP2016515518A patent/JP6194416B2/ja active Active
-
2015
- 2015-12-10 ZA ZA2015/09013A patent/ZA201509013B/en unknown
- 2015-12-15 CR CR20150663A patent/CR20150663A/es unknown
- 2015-12-21 IL IL243249A patent/IL243249A0/en active IP Right Grant
-
2016
- 2016-02-04 PH PH12016500249A patent/PH12016500249A1/en unknown
- 2016-03-25 MA MA38935A patent/MA38935B1/fr unknown
- 2016-03-30 CL CL2016000728A patent/CL2016000728A1/es unknown
- 2016-04-07 US US15/093,366 patent/US10004817B2/en active Active
-
2018
- 2018-05-15 US US15/980,080 patent/US11058781B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38935B1 (fr) | Dérivés de diazacarbazole à titre de ligands tau-pet | |
| EA202090255A3 (ru) | 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов | |
| FR2926554B1 (fr) | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique | |
| MA38175A1 (fr) | Lactames fusionnés à un aryle et hétéroaryle | |
| MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| MA34450B1 (fr) | Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique | |
| MA38138A1 (fr) | Dérivés inédits de quinolone | |
| MA38647B1 (fr) | Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x | |
| BR112014029006A2 (pt) | derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral | |
| MA38999A1 (fr) | Nouveaux composés hétérocycliques | |
| MA38385A1 (fr) | Nouvelle composition pour la stéatose hépatique non alcoolique (nafld) | |
| MA37142B1 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
| MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MX2016003422A (es) | Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen. | |
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| ZA202006439B (en) | Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators | |
| MX2015014353A (es) | Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina. | |
| MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA35878B1 (fr) | Utilisation thérapeutique de dérivés d'imidazopyridine | |
| MA38354B1 (fr) | Préparation contenant un composé de benzothiazolone | |
| MA37849A1 (fr) | Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux | |
| TH2001006044A (th) | อนุพันธ์ของพิราโซ-เททระไฮโดรไอโซควิโนลีนในฐานะเป็นตัวควบคุมเชิงบวกของตัวรับโดพามีน d1 |